UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

Cell metabolism, 2016-03, Vol.23 (3), p.427-440

2016

Volltextzugriff (PDF)

Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury

Toxicological sciences, 2008-09, Vol.105 (1), p.97-105

2008

Volltextzugriff (PDF)

Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice

PloS one, 2015-03, Vol.10 (3), p.e0119104-e0119104

2015

Volltextzugriff (PDF)

Stochastic gene expression out-of-steady-state in the cyanobacterial circadian clock

Nature, 2007-12, Vol.450 (7173), p.1249-1252

2007

Volltextzugriff (PDF)

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome

Drug metabolism and disposition, 2017-05, Vol.45 (5), p.501-511

2017

Volltextzugriff (PDF)

Probing Polymerization Forces by Using Actin-Propelled Lipid Vesicles

Proceedings of the National Academy of Sciences - PNAS, 2003-04, Vol.100 (8), p.4521-4526

2003

Volltextzugriff (PDF)

Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities

Scientific reports, 2018-05, Vol.8 (1), p.7781-7, Article 7781

2018

Volltextzugriff (PDF)

Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

Diabetes, obesity & metabolism, 2017-12, Vol.19 (12), p.1762-1772

2017

Volltextzugriff (PDF)

Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents

Journal of medicinal chemistry, 2018-07, Vol.61 (13), p.5704-5718

2018

Volltextzugriff (PDF)

Physiologically relevant binding affinity quantification of monoclonal antibody PF‐00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation

British journal of pharmacology, 2017-01, Vol.174 (1), p.70-81

2017

Volltextzugriff (PDF)

Analysis of Mechanistic Pathway Models in Drug Discovery: p38 Pathway

Biotechnology progress, 2008-01, Vol.24 (1), p.96-109

2008

Volltextzugriff (PDF)

Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro

BMC systems biology, 2010-03, Vol.4 (1), p.23-23, Article 23

2010

Volltextzugriff (PDF)

Comprehensive mechanism-based antibody pharmacokinetic modeling

2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2011, Vol.2011, p.4318-4323

2011

Volltextzugriff (PDF)

1 – 13 von 13

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(12)
Tagungsberichte
(1)

Sprache

Englisch
(13)
Japanisch
(5)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury

Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice

Stochastic gene expression out-of-steady-state in the cyanobacterial circadian clock

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome

Probing Polymerization Forces by Using Actin-Propelled Lipid Vesicles

Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities

Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents

Physiologically relevant binding affinity quantification of monoclonal antibody PF‐00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation

Analysis of Mechanistic Pathway Models in Drug Discovery: p38 Pathway

Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro

Comprehensive mechanism-based antibody pharmacokinetic modeling

Aktive Filter

Suchergebnisse filtern